<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511692</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1589</org_study_id>
    <secondary_id>2006-000377-30</secondary_id>
    <nct_id>NCT01511692</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects
      of liraglutide on energy intake in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The energy intake at a standardised buffet meal without a preload paradigm quantified using Foodworks 2.10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macronutrient distribution of food consumed at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macronutrient distribution of food consumed at a standardised buffet meal without a preload paradigm quantified using Foodworks 2.10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of eating at the buffet meal (satiation)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lira --&gt; placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo --&gt; glim</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glim --&gt; lira</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.8 mg/day injected subcutaneously for 4 weeks</description>
    <arm_group_label>Lira --&gt; placebo</arm_group_label>
    <arm_group_label>Glim --&gt; lira</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo, injected subcutaneously for 4 weeks</description>
    <arm_group_label>Lira --&gt; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks</description>
    <arm_group_label>Placebo --&gt; glim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>Dose individually adjusted, administered orally for 4 weeks</description>
    <arm_group_label>Placebo --&gt; glim</arm_group_label>
    <arm_group_label>Glim --&gt; lira</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic
             drug) mono-therapy

          -  HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD
             treated subjects: HbA1c between 6.5-9.5% (both inclusive)

          -  Body mass index (BMI) between 27-40 kg/m^2 (both inclusive)

          -  Subjects should have a stable body weight for at least 3 months prior to screening (as
             documented by a weight within 3 to 6 months, prior to screening that is within 15% of
             the screening weight)

          -  Euthyroid subjects

          -  Subjects should be unrestrained eaters

        Exclusion Criteria:

          -  Recurrent severe hypoglycaemia

          -  Impaired liver function

          -  Impaired renal function

          -  Cardiac problems

          -  Uncontrolled treated/untreated hypertension

          -  Known or suspected allergy to trial products or related products

          -  Use of any drug (except for OADs), which in the investigator's opinion could interfere
             with the subject's glucose level or body weight

          -  Active hepatitis B and/or active hepatitis C

          -  Positive HIV (human immunodeficiency virus) antibodies

          -  Known or suspected abuse of alcohol or narcotics

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, cola drinks, chocolate) as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012 Aug;97(2):258-66. doi: 10.1016/j.diabres.2012.02.016. Epub 2012 Mar 24.</citation>
    <PMID>22446097</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

